Searched for
RETAIL MODEL ONCOLOGY
For investors with patience, experience, and anxiety appetite: 5 stocks from different sectors with upside potential of up to 21%For the last five years, the theme on the street has mostly been: Buy today, expect comfort tomorrow. But some of the better wealth-creatin...- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsWhat we are witnessing in the market these days is similar to scenarios that have played out in the past. There have been many points in th...
- Invicta Diagnostic shares list at 18% premium over IPO price on NSE SME platformInvicta Diagnostic shares opened strong on D-Street, listing at an 18% premium. The IPO saw moderate demand across investor categories. The...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsAre valuations in the mid-cap segment now fairly priced? No. Does it mean you should avoid the segment altogether? The answer is again no. ...
- Eli Lilly and Visa expected to hit $1 trillion valuation by 2030: Here’s what’s driving the surgeAs global equity markets expand, two corporate heavyweights are emerging as serious contenders to reach $1 trillion in market capitalizatio...
- Everhope Oncology raises $10 million to bring retail model for cancer care in IndiaThis JV between Narayana Health Group, health-focussed early-stage venture fund W Health Ventures and its venture studio 2070 Health, will ...
- Reliance spends $13 bn on acquisitions in five yearsReliance Industries Ltd, led by Mukesh Ambani, has invested USD 13 billion in acquisitions over the past five years, focusing on new energy...
- Concord Biotech to list on Friday. Here’s what GMP suggestsAnalysts are of the opinion that a market premium of over 15% on the issue price is justified based on the company's business model, which ...
- Looking forward: Healthtech in 2023The healthtech ecosystem in India has flourished since the onset of the pandemic, and several scaled healthcare startups have emerged. Gear...
- Gland Pharma in high demand ahead of listingGland Pharma shares were available at a premium of Rs 20 in the grey market during the offer subscription period between Nov 9 and 11. The ...
- Gland Pharma IPO: Issue date, price band & other key detailsThe drugmarker will likely announce the name of anchor investors by the end of Friday.
- 5 mid-cap stocks that are worth investing in nowWe have zeroed in on five stocks which have seen their PE multiple soften by over 20% since December last year, making them attractive.
- Ideas to Innovation series: In conversation with the EY Entrepreneur of the Year Award Winner 2017 (Part 6)Exclusive interview with Sunder Genomal, Managing Director, Page Industries and Glenn Saldanha, Chairman and MD, Glenmark Pharmaceuticals
- ET Startup Awards 2017: ET-Facebook woman ahead award goes to Falguni Nayar of NykaaAn IIM- Ahmedabad alumna, Nayar founded Nykaa in 2012 after quitting as MD of Kotak Mahindra Capital Company, where she had spent 18 years.
- Laurus Labs debuts at Rs 490 on BSE, 14.5% premium to issue priceThe drugmaker sold its Rs 1,332 crore initial public offering (IPO) between December 6 and December 8, which was subscribed 4.52 times.
- Ratan Tata invests in cancer therapeutic startup Invictus OncologyThe startup utilises a supramolecular technology platform to design anti-cancer drugs that home into the tumor and modulate the tumor immun...
- Soon, cancer medicines, stents to be cheaperAfter the feedback, the health ministry decided to extend CGHS kind of mechanism to cancer medicines and stents for other consumers also, t...
- Aurobindo Pharma targets a revenue of over $3 billion by 2017-18Aurobindo Pharma is targeting a revenue of over $3 billion (over Rs 19,800 crore) by 2017-18 and plans to expand its basket with drugs to t...
- Aurobindo Pharma to expand product basket; eyes $3 billion revenues by FY18Aurobindo is targetting a revenue of over $ 3 billion by 2017-18 and plans to expand its basket with new drugs to treat cancer.
- Marksans Pharma buys UK's RelonchemMid-sized pharma firm Marksans Pharma has acquired UK’s leading generic drug marketing and distribution company Relonchem for Rs 100 crore.
Load More
